Latest Biologicals News

New Zealand King Salmon reported an FY25 net loss driven by a shortened reporting period and biological challenges, while advancing its Blue Endeavour pilot project despite delays. The company projects a cautious recovery in FY26 with EBITDA guidance between NZD 9 million and 15 million.

New Zealand King Salmon reports a $6.3 million net loss for an eight-month FY25 period, reflecting operational challenges and a shortened reporting cycle, while outlining cautious optimism for FY26 with targeted growth investments.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Syntara Limited has successfully completed Phase 1a trials for its topical anti-fibrotic drug SNT-9465, demonstrating dose-dependent target engagement and safety, and is now progressing to an innovative Phase 1b study in hypertrophic scars.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.

Mesoblast has achieved a landmark FDA approval for RYONCIL, the first allogeneic mesenchymal stromal cell therapy, driving strong commercial momentum and advancing a robust pipeline targeting inflammatory diseases.

Island Pharmaceuticals has secured membership in the Medical Countermeasures Coalition, positioning its antiviral Galidesivir for critical US government stockpiling and regulatory milestones.

Bio-Gene Technology reports significant progress in developing its bio-insecticides Flavocide and Qcide, including new efficacy data and organic certification, positioning the company for growth amid rising global demand for safer pest control.

Terragen Holdings has secured a major purchase order from Mort & Co Fertilisers for its Great Land Plus® bio-stimulant, projecting a significant sales boost in 2026. This deal underscores growing demand for sustainable agricultural solutions.

Algorae Pharmaceuticals has launched AlgoraeOS Version 2, a major AI platform upgrade that surpasses leading models including those from Google DeepMind, promising to accelerate drug-combination discovery.

Monash University has secured a $799,866 Australian Research Council grant to study brain injury thresholds using HITIQ’s PROTEQT™ instrumented mouthguards, with a $200,000 pre-order confirming commercial momentum.

KNeoMedia reports significant progress toward ASX reinstatement, driven by strategic capital raises and the expansion of its KneoScience platform into New York high schools, boosting potential revenue and student reach.